Company intelligence / Profile preview

Jiangsu Renocell Biotech

Unknown, Jiangsu*?, Chinaprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Jiangsu Renocell Biotech is developing RY_SW01, a mesenchymal stem cell injection therapy. Preclinical results showed significant improvement in urine biochemical indicators and tissue damage in animal models of lupus nephritis with excellent safety. The ongoing clinical trials include a Phase 2 study for lupus nephritis and scleroderma. The product aims to reduce the need for immunosuppressive drugs, potentially improving quality of life for patients with autoimmune kidney disease or systemic sclerosis. No approved products yet.

Therapeutic areas: ImmunologyRheumatology
Modalities: Cell therapy (specifically mesenchymal stem cell therapy)
Industry: Biotech

Drug pipeline

1 asset

89zr-oxine-ry_sw01

Beyond the preview

Go deeper on Jiangsu Renocell Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Renocell Biotech.

Explore the full profile